Therapeutic Asset Ratings
409 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Bl-M07D1
Ovarian Cancer
SystImmune Inc.
P1
C
(36)
Bl-M17D1
Ovarian Cancer
SystImmune Inc.
P1
C
(36)
Botensilimab
Ovarian Cancer
Agenus Inc.
P1
C
(36)
cct303-406
Ovarian Cancer
Shanghai PerHum Therapeutics Co., Ltd.
P1
C
(36)
cd70-targeting car-t cells
Ovarian Cancer
Chongqing Precision Biotech Co., Ltd
P1
C
(36)
cht101
Ovarian Cancer
Zhejiang University
P1
C
(36)
cirtociclib
Ovarian Cancer
Blueprint Medicines Corporation
P1
C
(36)
Clsp-1025
Ovarian Cancer
Clasp Therapeutics, Inc.
P1
C
(36)
CryptiVax-1001
Ovarian Cancer
Epitopea Ltd
P1
C
(36)
Cusp06
Ovarian Cancer
OnCusp Therapeutics, Inc.
P1
C
(36)
DNA, D(P-THIO)(T-G-A-C-T-G-T-G-A-A-C-G-T-T-C-G-A-G-A-T-G-A) UNCOSASODIUM
Ovarian Cancer
PhotonPharma, Inc.
P1
C
(36)
DPA-714
Ovarian Cancer
University of Alabama at Birmingham
P1
C
(36)
dr-0202
Ovarian Cancer
Dren Bio
P1
C
(36)
dt2216
Ovarian Cancer
Elizabeth Stover, MD, PhD
P1
C
(36)
exs74539
Ovarian Cancer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
C
(36)
Follicle Stimulating Hormone Receptor T Cells
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
P1
C
(36)
ft536
Ovarian Cancer
Masonic Cancer Center, University of Minnesota
P1
C
(36)
ft836
Ovarian Cancer
Fate Therapeutics
P1
C
(36)
Grt-C903
Ovarian Cancer
National Cancer Institute (NCI)
P1
C
(36)
Grt-R904
Ovarian Cancer
National Cancer Institute (NCI)
P1
C
(36)
hs-10502
Ovarian Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(36)
HUMAN FAECAL MATTER
Ovarian Cancer
M.D. Anderson Cancer Center
P1
C
(36)
Hwk-007
Ovarian Cancer
Whitehawk Therapeutics, Inc.
P1
C
(36)
ic9-car.b7-h3 t cells
Ovarian Cancer
UNC Lineberger Comprehensive Cancer Center
P1
C
(36)
Ide-161
Ovarian Cancer
IDEAYA Biosciences
P1
C
(36)
Showing 301 to 325 of 409 assets
Previous
Page 13 of 17
Next